Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.50
Bid: 33.00
Ask: 34.00
Change: 1.00 (3.08%)
Spread: 1.00 (3.03%)
Open: 32.50
High: 35.50
Low: 32.50
Prev. Close: 32.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: YouGov, Sareum and InterQuest...

Tue, 07th Aug 2012 11:25

Environmental Recycling Technologies, which owns the rights to the Powder Impression Moulding (PIM) process which is capable of converting mixed waste plastics into commercially viable products, has confirmed that its US parent application, entitled 'Process for Forming Plastic, Apparatuses for Forming Plastic and Articles Made Therefrom', has been granted by the US Patent Office. This is ERT's core patent in the US for the PIM process. Sareum, a specialist cancer drug discovery business, has said it notes the recent significant rise in its share price and has confirmed that "advanced stages of negotiations are taking place with a potential licencing partner". It added these "may or may not lead to a licencing agreement regarding one of the company's research programmes". Shares were up 184% on Tuesday, equal to 1.15p. The stock has gained 42% over the past year, and 163% in the past month. YouGov, the online market research firm, is anticipating that its operating profit will be in line with expectations with second half revenue similar to that achieved in the first half, reflecting the firm's focus on profitability in the German business and the expected end to a long-term contract in Iraq. The firm said its balance sheet remains strong with cash at July 31st of around £7.0m. TClarke, a building services company, reported a decline in pre-tax profit for the half year at £0.5m (2011: £1.4m) on revenues of £90.7m (2011: £92.6m), with the profit margin also lower at 0.5% compared to 1.5% the previous year. Basic earnings per share dropped from 2.38p to 0.79p, while net cash climbed £0.1m to £0.7m. The interim dividend was maintained at 1p per share. The firm blamed a lack of confidence across the sector for the declines and said that with a number of projects due to begin shortly it is confident of significant revenue progress in the second half. Shares in InterQuest Group, a specialist information technology recruitment group, took a hit after it admitted earnings before interest, tax, depreciation and amortisation are expected to be down year-on-year, in the region of £1.15m (2011: £1.86m), and warned the impact of investments and restructuring on profitability for 2012 will be around £1.6m. Trading conditions were poor in both the UK and Far East, particularly in the second quarter and particularly in the banking and finance sectors from which it derives 27% of its net fee income. This has meant profitability from investments has taken longer than anticipated. NR
More News
7 Oct 2021 22:08

TRADING UPDATES: Marlowe buys; Galliford snaps up nmcn's Water unit

TRADING UPDATES: Marlowe buys; Galliford snaps up nmcn's Water unit

Read more
19 Aug 2021 14:25

IN BRIEF: Sareum expects annual loss to widen, increases R&D

IN BRIEF: Sareum expects annual loss to widen, increases R&D

Read more
19 Aug 2021 07:41

Sareum expects FY losses to widen on higher R&D costs, supply delays

(Sharecast News) - British drugmaker Sareum said on Thursday that it expects to post a widened full-year loss as a result of increased research-and-development expenditure and delays in compound supply.

Read more
9 Aug 2021 17:08

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

Read more
6 Aug 2021 15:00

Sareum positive on SRA737 outlook after Sierra call

(Sharecast News) - Specialist drug development company Sareum noted on Friday that Sierra Oncology, the licence holder for the novel Chk1 inhibitor 'SRA737', had discussed its newly-announced global in-licensing agreement with AstraZeneca for AZD5153 with investors, which is a novel BRD4 BET inhibitor, to expand its myelofibrosis pipeline.

Read more
30 Jul 2021 19:40

TRADING UPDATES: Capita and Custodian REIT agree disposals

TRADING UPDATES: Capita and Custodian REIT agree disposals

Read more
30 Jul 2021 11:00

AIM WINNERS & LOSERS: Sareum in patent boost; Airea flags uncertainty

AIM WINNERS & LOSERS: Sareum in patent boost; Airea flags uncertainty

Read more
19 Jul 2021 19:13

TRADING UPDATES: Sareum raises GBP1 million; Marlowe buys Core Stream

TRADING UPDATES: Sareum raises GBP1 million; Marlowe buys Core Stream

Read more
1 Jul 2021 19:26

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

Read more
1 Jul 2021 11:18

Sareum releases 'encouraging' results from Covid-19 research

(Sharecast News) - Specialist drug development company Sareum announced "encouraging" top-line results from its UKRI grant-funded Covid-19 research project on Thursday.

Read more
15 Jun 2021 20:28

TRADING UPDATES: Tremor Nasdaq IPO underway; MGC's CannEpil in Ireland

TRADING UPDATES: Tremor Nasdaq IPO underway; MGC's CannEpil in Ireland

Read more
1 Jun 2021 17:43

TRADING UPDATES: Breedon buys Micromix; Marlowe acquires Alarm

TRADING UPDATES: Breedon buys Micromix; Marlowe acquires Alarm

Read more
1 Jun 2021 11:30

AIM WINNERS & LOSERS: Sound Energy falls on Morocco tax notification

AIM WINNERS & LOSERS: Sound Energy falls on Morocco tax notification

Read more
25 May 2021 17:11

TRADING UPDATES: Mothercare sales down; Revolution Bars seeks to raise

TRADING UPDATES: Mothercare sales down; Revolution Bars seeks to raise

Read more
25 May 2021 10:56

Sareum's pre-clinical development of SDC-1801 delayed by Covid-19

(Sharecast News) - Pharmaceutical company Sareum said on Tuesday that Covid-19 has continued to impact the contract research organisations it was working to complete pre-clinical development of its SDC-1801 drug candidate for autoimmune disease.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.